Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for ivonescimab, announced a clinical collaboration with Pfizer (NYSE: PFE) to evaluate the combination of ivonescimab, Akeso’s PD-1/VEGF bispecific antibody (BsAb), with Pfizer’s antibody drug conjugates (ADCs) in multiple solid tumors.
Collaboration Details
Under the agreement, Summit will provide ivonescimab for the studies, while Pfizer will conduct the operations. Both parties will oversee the trials, which are set to begin in mid-2024. The studies will assess ivonescimab combined with Pfizer’s vedotin ADCs.
Ivonescimab Background
Ivonescimab, the world’s first PD-1/VEGF BsAb, was licensed to Summit by Akeso in a $5 billion deal in 2022 for development in the U.S., Canada, Europe, and Japan. The partnership expanded in June 2023, granting Summit rights in Central and South America, the Middle East, and Africa.-Fineline Info & Tech
Leave a Reply